Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient
Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
1 .- 41 . (canceled)
42 . A method for the treatment of chronic obstructive pulmonary disease (COPD), comprising:
orally administering daily to a patient in need thereof an immediate release solid dosage form of 500 μg of a PDE 4 inhibitor that is N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast) or a salt thereof, and one or more suitable pharmaceutical excipients.
43 . The method of treatment according to claim 42 , wherein the PDE 4 inhibitor is roflumilast.
44 . The method of treatment according to claim 42 , wherein the immediate release solid dosage form is a tablet.
45 . The method of treatment of claim 44 , wherein the PDE 4 inhibitor is roflumilast.
46 . A method for the treatment of chronic obstructive pulmonary disease (COPD), comprising:
orally administering to a patient in need thereof an immediate release oral solid dosage form in tablet or pellet form containing 500 μg of N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast) or a salt thereof, and one or more suitable pharmaceutical excipients.
47 . The method of treatment of claim 46 wherein said immediate release oral dosage form is administered once per day.
48 . The method of treatment of claim 46 wherein said patient is suffering from chronic obstructive pulmonary disease.
49 . The method of treatment of claim 46 , wherein said immediate release oral solid dosage form in tablet or pellet form contains 500 μg of N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast).
50 . The method of treatment of claim 47 , wherein said immediate release oral solid dosage form in tablet or pellet form contains 500 μg of N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast).
51 . The method of treatment of claim 48 , wherein said immediate release oral solid dosage form in tablet or pellet form contains 500 μg of N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast).